Key statistics
As of last trade BIOMARIN PHADRN (B1MR34:SAO) traded at 191.52, 1.96% above its 52-week low of 187.84, set on Sep 24, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 191.52 |
---|---|
High | 191.52 |
Low | 191.52 |
Bid | -- |
Offer | 195.00 |
Previous close | 191.52 |
Average volume | 8.00 |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Nov 14 2024 09:44 GMT.
More ▼
Press releases
- BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024
- BioMarin to Participate in Three Upcoming Investor Conferences
- BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook
- BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET
- BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting
- BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance
- BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time
- BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY
More ▼